17β-Estradiol improves osteoblastic cell function through the Sirt1/NF-κB/MMP-8 pathway. (3rd July 2020)

• Record Type: Journal Article
• Authors: Zuo, H.-L.; Xin, H.; Yan, X.-N.; Huang, J.; Zhang, Y.-P.; Du, H.
• Is Part Of: Climacteric. Volume 23:Number 4(2020)
• Page Start: 404
• Page End: 409
• Publication Date: 2020-07-03
• Subjects: Postmenopausal osteoporosis -- 17β-estradiol -- osteoblasts -- matrix metalloproteinase-8 -- Sirtuin-1 -- nuclear transcription factor-κB; Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.1080/13697137.2020.1758057
• Languages: English
• ISSNs: 1369-7137

Abstract

Abstract: Objective: This study aims to investigate the beneficial effects of 17β-estradiol supplementation on the function of osteoblastic cells through the Sirtuin-1/nuclear transcription factor-κB/matrix metalloproteinase-8 (Sirt1/NF-κB/MMP-8) pathway. Methods: Mouse primary osteoblasts were obtained from neonatal mouse calvaria, and the cells were treated with or without 17β-estradiol. We first detected the effect of 17β-estradiol on the function of osteoblastic cells. Then, the changes in estrogen receptor-α (ERα), Sirt1, NF-κB, and MMP-8 were determined after the osteoblasts were treated with 17β-estradiol. During supplementation with 17β-estradiol, knockdown of Sirt1 in osteoblasts was used to further measure the changes of NF-κB and MMP-8 and observe the cell function. Results: In primary osteoblastic cells, exposure to 17β-estradiol improved cell viability and increased the levels of bone formation biomarkers, including osteocalcin, osteoprotegerin (OPG), procollagen type 1 N-terminal propeptide (P1NP), and alkaline phosphatase (ALP). In addition, 17β-estradiol supplement activated ERα and Sirt1 expression and inhibited NF-κB and MMP-8 expression. Moreover, these effects induced by 17β-estradiol were reversed by knockdown of Sirt1 in mouse primary osteoblasts. Conclusion: 17β-Estradiol replacement therapy may treat postmenopausal osteoporosis by improving osteoblastic cell function via the Sirt1/NF-κB/MMP-8 pathway.